LtaS-IN-1 (compound 1771) 是一种高效的小分子脂磷壁酸 (LTA) 抑制剂，可抑制耐多药 (MDR) 大肠杆菌中脂磷壁酸 (LTA) 的合成，并可改变细胞壁的形态。LtaS-IN-1 单独使用抑制肠球菌的生长的 MIC 值范围从 0.5 μg/mL 到 64 μg/mL。LtaS-IN-1 与抗生素联合使用几乎可以完全抑制耐多药的大肠杆菌生长。
| Cas No. | 877950-01-1 |
| Canonical SMILES | O=C(OCC(NC1=NN=C(C2=CC=CC=C2)O1)=O)CC3=COC4=CC=C5C=CC=CC5=C43 |
| 分子式 | C24H17N3O5 |
| 分子量 | 427.41 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | LtaS-IN-1 (compound 1771) is a potent small-molecule inhibitor of Lipoteichoic acid (LTA) synthesis in multidrug-resistant (MDR) E. faecium and by altering the cell wall morphology. LtaS-IN-1 alone inhibits Enterococcus.spp 28 strains with varying MIC values ranging from 0.5 μg/mL to 64 μg/mL. LtaS-IN-1 combination with antibiotics abolishs multidrug-resistant E. faecium growth almost completely[1]. [1]. Paganelli FL, et al. Lipoteichoic acid synthesis inhibition in combination with antibiotics abrogates growth of multidrug-resistant Enterococcus faecium.Int J Antimicrob Agents. 2017 Mar;49(3):355-363. |
